Vebreltinib before surgery for MET-altered lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a drug called Vebreltinib given before surgery for non-small cell lung cancer that has a specific change in the MET gene. The goal is to see if it can shrink tumors and make surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer (NSCLC) that is stage IIIA to IIIB (N2) and can be removed with surgery.
- You are 18 years or older.
- Your tumor has either a MET exon 14 skipping mutation or MET amplification (confirmed by a genetic test).
- You are in good overall health (ECOG score 0 or 1) and your lung function is good enough for surgery.
- You have not had previous targeted therapy, immunotherapy, or other trial drugs for your lung cancer.
- You are willing to use effective birth control during and for at least 120 days after treatment (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called vebreltinib before surgery for people with a specific type of lung cancer (MET exon 14 skipping mutation) that is at a stage where it can be removed. The goal is to see if the drug can shrink the tumor before surgery, making the operation more successful.
This trial tests a new drug called vebreltinib combined with standard chemotherapy for advanced non-small cell lung cancer (a common type of lung cancer) in patients whose tumors show high levels of a protein called MET. The goal is to see if this combination can slow cancer growth better than chemotherapy alone.
This trial tests a targeted drug (Vebreltinib) combined with standard chemotherapy in people with a specific type of advanced non-squamous lung cancer that has a MET gene change (amplification or overexpression). The goal is to see if this combination works better than chemo alone.
This trial tests a combination of two targeted drugs (Vebreltinib and PLB1004) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has developed MET amplification or overexpression after previous EGFR-targeted therapy. The goal is to see if this combination can help shrink tumors or slow their growth.
This study tests a new targeted pill (vebreltinib) for people with advanced non-small cell lung cancer that has a specific gene change (MET exon 14 mutation). It is for people who have not had much or any prior treatment. The goal is to see if this medicine can shrink tumors and improve outcomes.
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
Hear when a new Potentially Resectable MET-altered Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.